Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

19-01-2018

Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

designer491 / iStockphoto.com

Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).


Restasis, patent review, inter partes review, PTAB, Allergan, Saint Regis Mohawk Tribe, Mylan, PTAB

LSIPR